Loading...

Jo Chien, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7070
ORCID ORCID Icon0000-0003-2978-6249 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard UniversityM.D.2003School of Medicine

    Collapse Overview 
    Collapse Overview
    Dr. A. Jo Chien specializes in breast cancer, with special expertise in tumors that are called HER2+ (human epidermal growth factor receptor 2), typically a more aggressive type of cancer. Her primary research interests include HER2+, breast cancer in young women, and fertility problems related to cancer treatment.

    Chien graduated from Harvard Medical School in 2003 and completed a residency in internal medicine at Massachusetts General Hospital in Boston. She was a fellow in the hematology and oncology at UCSF from 2006 to 2009. Chien received the Massachusetts Medical Society and Alliance Charitable Foundation International Health Grant in 2003, American Society of Clinical Oncology (ASCO) Young Investigator Award in 2008; ASCO Foundation Merit Award in 2008; and American Cancer Society Postdoctoral Fellowship in 2008. She has published numerous articles in medical journals related to her breast cancer research. Chien is a member of the American Society of Clinical Oncology and the American Association of Cancer Research. She is an assistant professor of medicine at UCSF.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    2. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy. Clin Breast Cancer. 2019 12; 19(6):443-449.e1. Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME. PMID: 31285177.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    3. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12. Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. PMID: 31016232.
      View in: PubMed   Mentions:
    4. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017 10 01; 32(10):2123-2129. Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien AJ, Rosen M. PMID: 28938748.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    5. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. PMID: 28790114.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    6. Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? J Clin Oncol. 2017 09 20; 35(27):3089-3091. PMID: 28783451.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28660429.
      View in: PubMed   Mentions: 1     Fields:    
    8. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28503722.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    9. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319. PMID: 27832260.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    10. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159. PMID: 28110902.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    12. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    13. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    14. HER2-positive breast cancer: is more treatment better? Lancet Oncol. 2016 Mar; 17(3):268-270. PMID: 26874902.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. PMID: 26208485.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    17. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. PMID: 24711549.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    18. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers. 2013 Apr 23; 28(1):17-23. PMID: 23015398.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    19. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. PMID: 23470967.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    21. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(1):1-12. PMID: 23143215.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    22. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. PMID: 22798157.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    23. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20. PMID: 22198412.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    24. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012 Mar 15; 118(6):1710-7. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. PMID: 21887678.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    25. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012 Apr 01; 118(7):1933-9. PMID: 21850728.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    26. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010 Mar; 9(2):335-46. Chien AJ, Rugo HS. PMID: 20175700.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    27. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    28. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer. Cancer Treat Res. 2009; 151:197-215. Jo Chien A, Rugo HS. PMID: 19593514.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    29. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. Chien AJ, Moasser MM. PMID: 18410794.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    30. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5305-12. Chien AJ, Goss PE. PMID: 17114665.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansPHPublic Health
    Jo's Networks
    Concepts (171)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (55)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑